What is the price-to-earnings ratio of ImpediMed?
The price-earnings ratio of ImpediMed is currently 11.89.
ImpediMed P/S 2024
ImpediMed P/S
11.89
Ticker
IPD.AX
ISIN
AU000000IPD8
As of Sep 12, 2024, ImpediMed's P/S ratio stood at 11.89, a -46.49% change from the 22.22 P/S ratio recorded in the previous year.
The ImpediMed P/S history
ImpediMed Aktienanalyse
What does ImpediMed do?
ImpediMed Ltd is an Australian company specializing in medical devices and technologies. They were founded in 1999 and have their headquarters in Brisbane, Australia. The company is a leading provider of bioimpedance measurement devices for the diagnosis, monitoring, and treatment of lymphatic, cardiac, and other medical conditions. They have a wide range of products used in various medical fields, including oncology, lymphology, and cardiology. Their main business model is based on the development and marketing of their bioimpedance measurement devices. They also provide training and support for medical personnel to optimize the use of their devices. ImpediMed specializes in the diagnosis and treatment of lymphedema in the oncology sector, particularly using their highly precise L-Dex® device. They also analyze body composition in the cardiology sector to determine the risk of heart diseases and develop personalized treatment approaches. In recent years, ImpediMed has expanded into the European market, particularly in lymphedema diagnosis and treatment. Overall, ImpediMed Ltd is an innovative company that focuses on medical devices and technologies for the diagnosis and monitoring of cardiac and lymphatic diseases. They provide important diagnostic capabilities to medical professionals and continue to focus on growth and expansion. ImpediMed ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/S Details
Decoding ImpediMed's P/S Ratio
ImpediMed's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.
Year-to-Year Comparison
Comparing ImpediMed's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.
Impact on Investments
The P/S ratio is instrumental for investors evaluating ImpediMed's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.
Interpreting P/S Ratio Fluctuations
Variations in ImpediMed’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.
Frequently Asked Questions about ImpediMed stock
How has the price-earnings ratio of ImpediMed changed compared to last year?
The price-to-earnings ratio of ImpediMed has increased by -46.49% fallen (meaning "decreased" or "dropped") compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of ImpediMed high compared to other companies?
Yes, the price-to-earnings ratio of ImpediMed is high compared to other companies.
How does an increase in the price-earnings ratio of ImpediMed affect the company?
An increase in the price-earnings ratio of ImpediMed would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of ImpediMed affect the company?
A decrease in the price-earnings ratio of ImpediMed would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of ImpediMed?
Some factors that influence the price-earnings ratio of ImpediMed are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does ImpediMed pay?
Over the past 12 months, ImpediMed paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ImpediMed is expected to pay a dividend of 0 AUD.
What is the dividend yield of ImpediMed?
The current dividend yield of ImpediMed is .
When does ImpediMed pay dividends?
ImpediMed pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of ImpediMed?
ImpediMed paid dividends every year for the past 0 years.
What is the dividend of ImpediMed?
For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.
In which sector is ImpediMed located?
ImpediMed is assigned to the 'Health' sector.
Wann musste ich die Aktien von ImpediMed kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of ImpediMed from 9/12/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 9/12/2024.
When did ImpediMed pay the last dividend?
The last dividend was paid out on 9/12/2024.
What was the dividend of ImpediMed in the year 2023?
In the year 2023, ImpediMed distributed 0 AUD as dividends.
In which currency does ImpediMed pay out the dividend?
The dividends of ImpediMed are distributed in AUD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von ImpediMed
Our stock analysis for ImpediMed Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ImpediMed Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
